查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1820180

疫苗合约製造市场报告，按疫苗类型（减毒疫苗、灭活疫苗、亚单位疫苗、类毒素疫苗、DNA疫苗）、工作流程（下游、上游）、应用（人类使用、兽医）和地区划分，2025 年至 2033 年

Vaccine Contract Manufacturing Market Report by Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based, DNA-based), Workflow (Downstream, Upstream), Application (Human Use, Veterinary), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

2024年全球疫苗合约製造市场规模达30亿美元。展望未来， IMARC Group预计到2033年市场规模将达到63亿美元，2025-2033年期间的成长率（CAGR）为8.45%。

疫苗合约生产是指将大规模疫苗生产外包给合约生产组织 (CMO)。这些组织提供多种服务，包括预製剂工作、製剂开发、方法开发、稳定性研究、临床前活动、註册批次和商业化生产。此外，他们还提供专业知识和创新技术，以扩展製药公司的生产链。目前，由于开发成本降低和生产方案复杂度降低，全球对疫苗生产活动外包的需求正在不断增长。

疫苗接种在改善人类和动物健康方面发挥关键作用。它减少了对抗生素的需求并预防疾病。人们对疫苗接种及其许多相关益处（例如预防重症和传染病）的认识日益提高，这刺激了对免疫接种计划和疫苗接种的需求。由于对生产资本需求复杂性的理解，领先的製药公司将疫苗生产外包。此外，资源匮乏的国家缺乏疫苗生产设备和熟练劳动力，也助长了全球疫苗合约生产市场的成长。此外，包括EB66和GPEx等表达系统以及细胞培养基平台的引入在内的技术进步正在支持市场成长。此外，许多国家冠状病毒病（COVID-19）病例的惊人增长促使疫苗开发商与合约生产企业（CMO）签署了外包协议。这为市场的成长创造了良好的前景。

本报告回答的关键问题

  • 疫苗合约生产市场有多大？疫苗合约生产市场未来前景如何？
  • 推动疫苗合约製造市场的关键因素有哪些？
  • 全球疫苗合约製造市场领先的公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球疫苗合约製造市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依疫苗类型

  • 减毒
  • 灭活
  • 基于亚基
  • 基于类毒素
  • 基于DNA

第七章：市场区隔：依工作流程

  • 下游
    • 关键部分
      • 填充和完成操作
      • 分析和品质控制研究
      • 包装
  • 上游
    • 关键部分
      • 哺乳动物表达系统
      • 细菌表现系统
      • 酵母表现系统
      • 桿状病毒/昆虫表现系统
      • 其他的

第 8 章：市场区隔：按应用

  • 人类使用
  • 兽医

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Ajinomoto Co. Inc.
    • Albany Molecular Research Inc
    • Catalent Inc
    • Cobra Biologics Limited (Charles River Laboratories International Inc.)
    • Cytovance Biologics Inc. (Hepalink USA Inc.)
    • Fujifilm Holdings Corporation
    • ICON plc
    • IDT Biologika GmbH
    • Lonza Group AG
    • Merck KGaA
    • Pharmaceutical Product Development LLC
    • PRA Health Sciences Inc.
Product Code: SR112025A3872

The global vaccine contract manufacturing market size reached USD 3.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.3 Billion by 2033, exhibiting a growth rate (CAGR) of 8.45% during 2025-2033.

Vaccine contract manufacturing refers to the outsourcing of large-scale production of vaccines to contract manufacturing organizations (CMOs). These organizations offer numerous services, including pre-formulation work, formulation development, method development, stability studies, pre-clinical activities, registration batches and commercial manufacturing. Apart from this, they provide expertise and innovative technologies to expand the production chain of pharmaceutical companies. At present, the demand for outsourcing vaccine manufacturing activities is escalating worldwide on account of reduced development costs and complex production protocols.

Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents diseases. The increasing awareness about vaccination and numerous associated benefits, such as protection from severe illnesses and infectious diseases, is catalyzing the demand for immunization programs and inoculations. This, in confluence with understanding the complexity of capital requirement for production, has led the leading pharmaceutical companies to outsource vaccine manufacturing. Apart from this, the lack of equipment and skilled labor for vaccine production in low-resource countries is also contributing to the global vaccine contract manufacturing market growth. Moreover, technological advancements, including the introduction of expression systems like the EB66 and GPEx and cell culture media platforms, are supporting the market growth. Furthermore, the alarmingly growing cases of coronavirus disease (COVID-19) in numerous countries have propelled the vaccine developers to sign outsourcing agreements with CMOs. This is creating a favorable outlook for the growth of the market.

Key Market Segmentation:

Breakup by Vaccine Type:

  • Attenuated
  • Inactivated
  • Subunit-based
  • Toxoid-based
  • DNA-based

Breakup by Workflow:

  • Downstream
    • Fill and Finish Operations
    • Analytical and QC Studies
    • Packaging
  • Upstream
    • Mammalian Expression Systems
    • Bacterial Expression Systems
    • Yeast Expression Systems
    • Baculovirus/Insect Expression Systems
    • Others

Breakup by Application:

  • Human Use
  • Veterinary

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaA, Pharmaceutical Product Development LLC and PRA Health Sciences Inc.

Key Questions Answered in This Report

  • 1.How big is the vaccine contract manufacturing market?
  • 2.What is the future outlook of vaccine contract manufacturing market?
  • 3.What are the key factors driving the vaccine contract manufacturing market?
  • 4.Which are the leading companies in the global vaccine contract manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Contract Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Attenuated
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Inactivated
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Subunit-based
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Toxoid-based
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 DNA-based
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Workflow

  • 7.1 Downstream
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Fill and Finish Operations
      • 7.1.2.2 Analytical and QC studies
      • 7.1.2.3 Packaging
    • 7.1.3 Market Forecast
  • 7.2 Upstream
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Mammalian Expression Systems
      • 7.2.2.2 Bacterial Expression Systems
      • 7.2.2.3 Yeast Expression Systems
      • 7.2.2.4 Baculovirus/Insect Expression Systems
      • 7.2.2.5 Others
    • 7.2.3 Market Forecast

8 Market Breakup by Application

  • 8.1 Human Use
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Veterinary
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Ajinomoto Co. Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Albany Molecular Research Inc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Catalent Inc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Fujifilm Holdings Corporation
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 ICON plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 IDT Biologika GmbH
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Lonza Group AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Merck KGaA
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Pharmaceutical Product Development LLC
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 PRA Health Sciences Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials

List of Figures

  • Figure 1: Global: Vaccine Contract Manufacturing Market: Major Drivers and Challenges
  • Figure 2: Global: Vaccine Contract Manufacturing Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Vaccine Contract Manufacturing Market: Breakup by Vaccine Type (in %), 2024
  • Figure 5: Global: Vaccine Contract Manufacturing Market: Breakup by Workflow (in %), 2024
  • Figure 6: Global: Vaccine Contract Manufacturing Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Vaccine Contract Manufacturing Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Vaccine Contract Manufacturing (Attenuated) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Vaccine Contract Manufacturing (Attenuated) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Vaccine Contract Manufacturing (Inactivated) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Vaccine Contract Manufacturing (Inactivated) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Vaccine Contract Manufacturing (Subunit-based) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Vaccine Contract Manufacturing (Subunit-based) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Vaccine Contract Manufacturing (Toxoid-based) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Vaccine Contract Manufacturing (Toxoid-based) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Vaccine Contract Manufacturing (DNA-based) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Vaccine Contract Manufacturing (DNA-based) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Vaccine Contract Manufacturing (Downstream) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Vaccine Contract Manufacturing (Downstream) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Vaccine Contract Manufacturing (Upstream) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Vaccine Contract Manufacturing (Upstream) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Vaccine Contract Manufacturing (Human Use) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Vaccine Contract Manufacturing (Human Use) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Vaccine Contract Manufacturing (Veterinary) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Vaccine Contract Manufacturing (Veterinary) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: North America: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: North America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: United States: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: United States: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Canada: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Canada: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Asia-Pacific: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Asia-Pacific: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: China: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: China: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Japan: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Japan: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: India: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: India: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: South Korea: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: South Korea: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Australia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Australia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Indonesia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Indonesia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Europe: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Europe: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Germany: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Germany: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: France: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: France: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: United Kingdom: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: United Kingdom: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Italy: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Italy: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Spain: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Spain: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Russia: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Russia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Latin America: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Latin America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Brazil: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Brazil: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Mexico: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Mexico: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Middle East and Africa: Vaccine Contract Manufacturing Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Middle East and Africa: Vaccine Contract Manufacturing Market: Breakup by Country (in %), 2024
  • Figure 74: Middle East and Africa: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Global: Vaccine Contract Manufacturing Industry: SWOT Analysis
  • Figure 76: Global: Vaccine Contract Manufacturing Industry: Value Chain Analysis
  • Figure 77: Global: Vaccine Contract Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Contract Manufacturing Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Vaccine Type (in Million USD), 2025-2033
  • Table 3: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Workflow (in Million USD), 2025-2033
  • Table 4: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Vaccine Contract Manufacturing Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Vaccine Contract Manufacturing Market: Competitive Structure
  • Table 7: Global: Vaccine Contract Manufacturing Market: Key Players